Xeris Pharmaceuticals | XERS - Current Assets



Xeris Pharmaceuticals reported $185.58M in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
Adcock Ingram Holdings ZAR 5.12B 234.71M Dec/2024
Celltrion KRW 5.46T 122.95B Mar/2025
Cspc Pharmaceutical CNY 21.89B 4.58B Dec/2024
Dianthus Therapeutics USD 263.6M 17.3M Jun/2025
Divis Laboratories Ltd 100.81B 7.4B Mar/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Kangmei Pharma CNY 6.9B 6.92M Jun/2025
Knight Therapeutics CAD 397.57M 36.96M Sep/2024
Laboratorios Farma EUR 516.3M 26.69M Jun/2025
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.41M 7.26M Dec/2024
Neuren Pharmaceuticals AUD 399.33M 171.29M Dec/2024
Organigram Holdings CAD 277.78M 46.29M Jun/2025
Pacira USD 745.61M 14.35M Jun/2025
Perrigo USD 2.62B 82M Jun/2025
Pharma Mar EUR 249.4M 13.39M Jun/2025
Qiagen NV USD 1.82B 76.12M Jun/2025
Sartorius EUR 2.17B 7.5M Jun/2025
Sino Biopharmaceutical CNY 24.69B 536.66M Dec/2024
Supernus Pharmaceuticals USD 738.87M 51.28M Jun/2025
Tilray USD 707.34M 18.54M Nov/2024
Zz Pientze Pharmaceu 12.29B 113.34M Jun/2025